COVID-19
Conditions
Brief summary
Patients requiring hospitalization due to COVID-19 pneumonia (non-severe) will be randomized to standard prophylactic doses or full therapeutic dose of bemiparin (a LMWH) for 10 days.
Interventions
DRUGBemiparin sodium
Prophilactic vs full-dose for 10 days
Sponsors
Clinica Universidad de Navarra, Universidad de Navarra
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age (equal or more than 18 yo) * Hospitalization at conventional wards due to COVID-19 related mild or moderate pneumonia (CURB65\<3 points; Sat. O2\>90%) * 3-4 points according to the WHO ordinal scale. * Confirmed COVID-19 (PCR or other validated test) * D-dimer \>500 ng/mL * Sign of informed consent * The patient is able, according to investigator's opinion, to deal with all the requirements of the clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical deterioration | 10 days | Combined outcome that includes number of patients who suffer any of the following: Death, ICU admission, mechanical ventilatory support, progression to moderate or severe ARDS (according to Berlin criteria) or arterial or venous thrombosis. |
Countries
Spain
Contacts
Primary ContactRamon Lecumberri, MD, PhD
Outcome results
None listed